POAI Predictive Oncology Inc: רווח למניה ב-12 החודשים האחרונים

Predictive Oncology management is integrating AI modeling into oncology, transitioning from science to commercialization. The year-over-year change in EPS (TTM) illustrates this trend, where -163.00 represents the latest metric level. The company is accelerating drug discovery via the largest tumor dataset, meeting the growing demand from biotech behemoths to optimize preclinical R&D research.

This indicator measures the percentage change in net earnings per share over a rolling year, smoothing out quarterly gaps to identify the true earnings trend. By analyzing the year-over-year EPS growth dynamics over a rolling period, investors can see how the high B2B authority of the Predictive Oncology (POAI) AI platform in oncopharmacology transforms into tangible financial results and increased shareholder value.